For healthcare professionals only

Letters Dabigatran v warfarin

Take real world issues into account

BMJ 2011; 343 doi: (Published 13 December 2011) Cite this as: BMJ 2011;343:d7716
  1. Arnold Zermansky, GP and senior research fellow1,
  2. Rani Khatib, senior pharmacist and lecturer1
  1. 1University of Leeds, Leeds, UK
  1. a.g.zermansky{at}

Pink and colleagues’ analysis of the economics of dabigatran is flawed by several real world issues that were not considered.1

Firstly, the price of dabigatran will fall as competitive drugs are licensed.

Secondly, the cost of stopping international normalised ratio (INR) monitoring depends on whether warfarin clinics continue to run but …

View Full Text

Log in

Log in through your institution


* For online subscription